Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
AlloVir, Inc. ALVR
$3.82
-$0.35 (-9.05%)
На 18:02, 12 мая 2023
+790.05%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
408178134.00000000
-
week52high
10.29
-
week52low
3.17
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.71945200
-
EPS
-2.38000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 12:30
Описание компании
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 28 июл 2022 г. |
| Piper Sandler | Overweight | Overweight | 19 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 10 февр 2022 г. |
| BMO Capital | Outperform | 01 февр 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 18 янв 2022 г. |
| Morgan Stanley | Overweight | Overweight | 09 сент 2022 г. |
| SVB Leerink | Outperform | Outperform | 07 ноя 2022 г. |
| Morgan Stanley | Overweight | Overweight | 27 янв 2023 г. |
| SVB Leerink | Outperform | Outperform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Brainard Diana | A | 1836875 | 617500 | 02 февр 2023 г. |
| Brainard Diana | A | 934964 | 332500 | 02 февр 2023 г. |
| Hagen Brett R | A | 251708 | 113750 | 02 февр 2023 г. |
| Hagen Brett R | A | 135254 | 61250 | 02 февр 2023 г. |
| Leen Ann M. | A | 473594 | 81250 | 02 февр 2023 г. |
| Leen Ann M. | A | 124006 | 43750 | 02 февр 2023 г. |
| Miller Edward | A | 497844 | 162500 | 02 февр 2023 г. |
| Miller Edward | A | 235958 | 87500 | 02 февр 2023 г. |
| Sinha Vikas | A | 1012362 | 292500 | 02 февр 2023 г. |
| Sinha Vikas | A | 1187738 | 157500 | 02 февр 2023 г. |
Новостная лента
AlloVir, Inc. (ALVR) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
25 янв 2023 г. в 13:32
AlloVir, Inc. (ALVR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8%
Zacks Investment Research
25 янв 2023 г. в 11:18
The mean of analysts' price targets for AlloVir, Inc. (ALVR) points to a 355.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
Business Wire
03 янв 2023 г. в 07:00
WALTHAM, Mass.--( BUSINESS WIRE )--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2023, at 2:15 p.m. PST.
AlloVir: Solid Data, But Market Isn't Paying Attention
Seeking Alpha
10 ноя 2022 г. в 13:27
AlloVir, Inc. has some solid data in an area of unmet need. AlloVir is well-capitalized to complete its trials.
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Business Wire
31 авг 2022 г. в 07:00
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference in New York on Wednesday, September 14, 2022, at 12:20 p.m. ET. A live webcast and archived replay of the fireside chat will be available on the Investors & Press section of the AlloVir website at https